.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP02_Telaprevir.Telaprevir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP02_Telaprevir.Telaprevir| name: | Telaprevir |
| ATC code: | J05AP02 | route: | oral |
| n-compartments | 2 |
Telaprevir is an oral antiviral drug that acts as a protease inhibitor, specifically inhibiting the NS3/4A protease of hepatitis C virus (HCV). It was used in combination with other agents for the treatment of chronic hepatitis C infection, genotype 1. While it was previously approved, telaprevir has been withdrawn from the market in many countries due to adverse effects and the development of more effective agents.
Pharmacokinetic model in adult healthy subjects and patients with chronic hepatitis C. Oral administration under fed conditions.
Kiang, TK, et al., & Ensom, MH (2013). Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clinical pharmacokinetics 52(7) 487–510. DOI:10.1007/s40262-013-0053-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/23553423
Gentile, I, et al., & Borgia, G (2014). Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. Reviews on recent clinical trials 9(2) 115–123. DOI:10.2174/1574887109666140529222602 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24882169
Klibanov, OM, et al., & Vickery, SB (2011). Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy 31(10) 951–974. DOI:10.1592/phco.31.10.951 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21950642